Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArcticZymes Technologies ASA's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.01.
During the past 3 years, the average EBIT per Share Growth Rate was -58.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for ArcticZymes Technologies ASA's EBIT per Share or its related term are showing as below:
FRA:B4V'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -58.5 Med: 15.5 Max: 595.5
Current: -58.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of ArcticZymes Technologies ASA was 595.50% per year. The lowest was -58.50% per year. And the median was 15.50% per year.
FRA:B4V's 3-Year EBIT Growth Rate is ranked worse than 95.65% of 1173
companies
in the Biotechnology industry
Industry Median: 15.5
vs FRA:B4V: -58.50
ArcticZymes Technologies ASA (FRA:B4V) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
ArcticZymes Technologies ASA EBIT per Share Related Terms
ArcticZymes Technologies ASA EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ArcticZymes Technologies ASA (FRA:B4V) has a EBIT per Share of €0.01 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ArcticZymes Technologies ASA and its competitors. According to the industry distribution chart, ArcticZymes Technologies ASA ranks #1122 out of 1173 companies in the Biotechnology industry, placing it in the top 95.7%.
Is ArcticZymes Technologies ASA's EBIT per Share too high?
ArcticZymes Technologies ASA's current EBIT per Share is €0.01. Based on the distribution chart, ArcticZymes Technologies ASA ranks #1122 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ArcticZymes Technologies ASA has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does ArcticZymes Technologies ASA's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ArcticZymes Technologies ASA ranks #1122 out of 1173 companies for EBIT per Share. This places ArcticZymes Technologies ASA in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ArcticZymes Technologies ASA and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ArcticZymes Technologies ASA's current EBIT per Share is €0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArcticZymes Technologies ASA stock overvalued right now?
ArcticZymes Technologies ASA (FRA:B4V) has a current EBIT per Share of €0.01. The stock's GF Value™ is €2.16, compared to a current price of €1.68 — trading 22.5% below its estimated fair value. The current EBIT per Share is €0.01. ArcticZymes Technologies ASA's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For ArcticZymes Technologies ASA (FRA:B4V), the current EBIT per Share is €0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ArcticZymes Technologies ASA (FRA:B4V) Overvalued in 2026?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA stock appears to be undervalued.
The current stock price of €1.68 is trading 22.5% below its estimated GF Value™ of €2.16.
Key valuation signals for FRA:B4V:
EBIT per Share: €0.01
GF Value™: €2.16 vs. price of €1.68 (22.5% below fair value)
No single metric tells the full story. See the FRA:B4V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
78GF Score
Get the complete analysis for FRA:B4V
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:B4V has been successfully added to your 
